Furthermore, in several other cancers, including lung cancer and colon cancers, HER2-targeted ADCs have proven effective in treating PDX models harboring pathogenic ERBB2 mutations [32,33,34]. This evidence concerns the gene ERBB2 and colonic neoplasm.